Controlling HIV epidemics among injection drug users: Eight years of cross-border HIV prevention interventions in Vietnam and China

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hammett, Theodore M ^a   Des Jarlais, Don C ^b   Kling, Ryan ^a   Kieu, Binh Thanh ^a   McNicholl, Janet M ^c   Wasinrapee, Punneeporn ^d   McDougal, J Stephen ^e   Liu, Wei ^f   Chen, Yi ^f   Meng, Donghua ^g   Doan, Ngu ^a   Huu Nguyen, Tho ^h   Ngoc Hoang, Quyen ⁱ   van Hoang, Tren ⁱ  

^a ABT ASSOCIATES   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Guangxi Center for Disease Control   (China)

^g Ning Ming County Health Department   (China)

^h Lang Son Provincial HIV/AIDS Center   (Viet Nam)

ⁱ Ha Giang Provincial Health Services   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHINA; CROSS-SECTIONAL STUDY; DRUG ABUSE; EPIDEMIC; FEMALE; HEALTH EDUCATION; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; SYRINGE; VIET NAM;

ADULT; CHINA; COMMUNICABLE DISEASE CONTROL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; INFECTIOUS DISEASE MEDICINE; INTERNATIONAL COOPERATION; MALE; PATIENT EDUCATION AS TOPIC; PEER GROUP; PREVALENCE; QUESTIONNAIRES; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; VIETNAM;

EID: 84865418621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043141     Document Type: Article

References (58)

1. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-45.
2. Commission on AIDS in Asia (2008) Redefining AIDS in Asia: crafting an effective response. Delhi: Oxford University Press.
3. Vietnam Administration for HIV/AIDS Control (Ministry of Health) and Family Health International (2009) 2007 HIV/AIDS estimates and projections. Hanoi: VAAC.
4. Ministry of Health, Joint United Nations Programme on HIV/AIDS, World Health Organization (2010) 2009 Estimates for the HIV/AIDS Epidemic in China. Beijing: Ministry of Health.
5. Institute of Medicine (2007) Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington: National Academies Press.
6. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376 (9737): 268-294.
7. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, et al. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376(9737): 285-301.
8. Sullivan SG, Wu Z, (2007) Rapid scale up of harm reduction in China. Int J Drug Policy 18: 118-128.
9. Hammett TM, Wu Z, Duc TT, Stephens D, Sullivan S, et al. (2008) "Social evils" and harm reduction: the evolving policy environment for HIV prevention among injection drug users in China and Vietnam. Addiction 103: 137-145.
10. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R, (2007) Evolution of China's response to HIV/AIDS. Lancet 369: 621-623.
11. Human Rights Watch (2010) "Where darkness knows no limits": incarceration, ill-treatment, and forced labor as drug rehabilitation in China. New York: Human Rights Watch.
12. Human Rights Watch (2011) The Rehab Archipelago: Forced Labor and Other Abuses in Drug Detention Centers in Southern Vietnam. New York: Human Rights Watch.
13. World Health Organization (2009) Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia, and Vietnam. Manila: WHO Western Pacific Region.
14. Wu Z, Luo W, Sullivan SG, Rou K, Lin P, et al. (2007) Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China. AIDS (Suppl 8): S115-122.
15. Ngo AD, Schmich L, Higgs P, Fischer A, (2009) Qualitative evaluation of a peer-based needle syringe programme in Vietnam. Int J Drug Policy 20: 179-182.
16. Des Jarlais DC, Kling R, Hammett TM, Ngu D, Liu W, et al. (2007) Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS (suppl 8): S109-S114.
17. Hammett TM, Kling R, Johnston P, Liu W, Ngu D, et al. (2006) HIV prevalence and HIV risk behaviors among injection drug users prior to and 24 months following implementation of cross-border interventions in Northern Vietnam and Southern China. AIDS Education and Prevention 18: 97-115.
18. Hammett TM, Bartlett NA, Chen Y, Ngu D, Cuong DD, et al. (2005) Law enforcement influences on HIV prevention for injection drug users: observations from a cross-border project in China and Vietnam. Int J Drug Policy16: 235-245.
19. Hammett TM, Norton GD, Kling R, Liu W, Chen Y, et al. (2005) Community attitudes toward HIV prevention for injection drug users: findings from a cross-border project in Southern China and Northern Vietnam. J Urban Health 82: 34-42.
20. Beyrer C, Razak MT, Lisam K, Chen J, Lui W, et al. (2000) Overland heroin trafficking routes and HIV-1 spread in South and South-East Asia. AIDS Res Hum Retroviruses 14: 75-83.
21. Des Jarlais DC, Johnston P, Friedmann P, Kling R, Liu W, et al. (2005) Patterns of HIV prevalence among injecting drug users in the cross-border area of Lang Son Province, Vietnam and Ning Ming County, Guangxi Province, China. BMCPublicHealth. 5: 89.
22. Hammett TM, Johnston P, Kling R, Liu W, Ngu D, et al. (2005) Correlates of HIV status among injection drug users in a border region of southern China and northern Vietnam. J Acquir Immune Defic Syndr 38: 228-235.
23. Weibel W (1993) The indigenous leader outreach model: intervention manual. (Levin LB-ed.). Rockville, MD: National Institute on Drug Abuse.
24. National Institute on Drug Abuse (1994) Outreach/Risk Reduction Strategies for Changing HIV-Related Risk Behaviors among Injection Drug Users: The National AIDS Demonstration Research (NADR) Project. Rockville, MD: NIDA.
25. Needle RH, Burrows D, Friedman S, Dorabjee J, Touze G, et al. (2003) Evidence for action: effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users. Geneva: WHO/UNAIDS.
26. Needle RH, Burrows D, Friedman SR, Dorabjee J, Touze G, et al. (2005) Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users. Intl J Drug Policy 16 (suppl 1): 45-57.
27. Broadhead R, Hammett TM. Kling R, Ngu D, Liu W, et al. (2009) Peer-driven interventions in Vietnam and China to prevent HIV: a pilot study targeting injection drug users. Journal of Drug Issues 39: 829-850.
28. Abt Associates Inc., Beth Israel Medical Center (2010) Cross-Border Project Implementation Manual. Hanoi: Abt Associates Inc.
29. Des Jarlais DC (2000) Structural interventions to reduce HIV transmission among injecting drug users. AIDS (suppl 1): S41-S46.
30. Cohen DA, Scribner R, (2000) An STD/HIV prevention intervention framework. AIDS Patient Care STDs 14: 37-45.
31. Stimson GV, Des Jarlais DC, Ball A, eds. (1998) Drug injecting and HIV infection: Global dimensions and local responses. London: UCL Press.
32. Parekh SS, Kennedy MS, Dobbs T, Pau C-P, Byers R, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 18: 295-307.
33. McDougal JS, Pilcher CD, Parekh BS, Gershy-Damet G, Branson BM, et al. (2005) Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS (suppl 2): S25-30.
34. McNicholl JM, McDougal JS, Wasinrapee P, Branson B, Martin M, (2011) Assessment of BED HIV-1 incidence assay in seroconverter cohorts: influence of individuals with long-term infection and importance of stable incidence over time. PLoS ONE 6(3): e14748 doi:10.1371/journal.pone.0014748.
35. Greene WH (2000) Econometric Analysis, Fourth Edition. Upper Saddle River, New Jersey: Prentice-Hall Inc.
36. SAS Institute Inc. (2008) SAS/STAT® 9.2 User's Guide. Cary, NC: SAS Institute Inc.
37. Cameron AC, Trividi PK (2003) Microeconometrics: Methods and Applications. New York: Cambridge University Press.
38. Jia M, Luo H, Ma Y, Wang N, Smith K, et al. (2010) The HIV epidemic in Yunnan Province, China, 1989-2007. J Acquir Immune Defic Syndr (suppl 1): S34-S40.
39. Liang K-Y, Zeger SL, (1986) Longitudinal data analysis using generalized linear models. Biometrika. 72: 13-22.
40. Wasinrapee P, Chaowanachan T, Martin M, Dobbs T, Prekh B (2004) Estimation of HIV-1 incidence from a cross-sectional assessment of injecting drug users using the HIV-1 BED subtype IgG-capture EIA. Poster MoPeC3561, presented at XV International AIDS Conference, Bangkok.
41. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, et al. (2011) Determination of mean recency period for estimation of HIV-1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265-273.
42. Wilson E, (1927) Probable inference, the law of succession, and statistical inference. Journal of the American Statistical Association 22: 209-212.
43. Welte A, McWalter TA, Barnighausen T, (2009) A simplified formula for inferring HIV incidence from cross-sectional surveys using a test for recent infection. AIDS Res Hum Retroviruses 25: 125-126.
44. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, et al. (2006) Comparison of HIV-1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 22: 945-952.
45. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, McDougal JS, et al. (2008) Improved HIV incidence estimates using the BED capture enzyme immunoassay. AIDS 22: 511-518.
46. Des Jarlais DC, Perlis T, Aresteh K, Torian LV, Beatrice S, et al. (2005) HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health 95: 1439-1444.
47. Semaan S, Des Jarlais DC, Sogolow E, Hedges LV, Ramirez G, et al. (2002) A meta-analysis of the effect of HIV prevention interventions on sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr (suppl 1): S73-93.
48. Hammett TM, Van NTH, Kling R, Binh KT, Oanh KTH, (2010) Female sexual partners of injection drug users in Vietnam: an at-risk population in urgent need of HIV prevention services. AIDS Care 22: 1466-1472.
49. Welte A, McWalter TA, Laeyendecker O, Hallett TB (2010) Using tests for recent infection to estimate incidence: problems and prospects for HIV. Euro Surveill 15(24): pii: 19589.
50. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, et al. (2010) Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 53: 496-499.
51. Hallett TB, Ghys P, Barnighausen T, Yan P, Garnett GP, (2009) Errors in "BED"-derived estimates of HIV incidence will vary by place, time, and age. PLoS One 4: e5720.
52. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, et al. (2012) Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses 28: 816-822.
53. Laeyendecker O, Brookmeyer R, Mullis C, Donnell D, Lingappa J (2012) Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known non-recent HIV infection from five African countries. AIDs Res Hum Retroviruses 2012, Jan 29 [Epub ahead of print].
54. Karita E, Prie M, Hunter E, Chomba E, Allen S, et al. (2007) Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 21: 403-408.
55. Havashida T, Gatanaga H, Tanuma J, Oka S, (2008) Effects of low HIV type 1 load and antiretroviral treatment on IgC-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 24: 495-498.
56. Brookmeyer R, (2009) Should biomarker estimates of HIV incidence be adjusted? AIDS 23: 485-491.
57. Office of Global AIDS Coordinator (2010) Update on HIV-1 Incidence Estimation and Surveillance in Resource-constrained Settings using Tests for Recent Infection - Statement from the Surveillance and Survey and the Laboratory Technical Working Groups to the Office of the Global AIDS Coordinator, September 2010. Washington DC: OGAC.
58. Quan VM, Minh NL, Ha TV, Ngoc NP, Vu PT, et al. (2010) Mortality and HIV transmission among male Vietnamese injection drug users. Addiction 106: 583-589.